| Acute Ischemic Stroke Management | Lifetime | 46 | CN 1 | 99.78 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 61 | CN 1 | 99.73 |
| Stroke Rehabilitation and Recovery | Lifetime | 60 | CN 1 | 99.58 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 141 | CN 1 | 99.53 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 92 | CN 2 | 99.48 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 93 | CN 5 | 99.10 |
| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 99 | CN 5 | 99.02 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 137 | CN 4 | 98.51 |
| Lipoproteins and Cardiovascular Health | Lifetime | 674 | CN 6 | 97.37 |
| Cardiovascular Health and Disease Prevention | Lifetime | 743 | CN 10 | 96.88 |
| Neurological and metabolic disorders | Lifetime | 289 | CN 2 | 94.57 |
| Neurosurgical Procedures and Complications | Lifetime | 815 | CN 24 | 93.75 |
| Healthcare Systems and Practices | Lifetime | 893 | CN 5 | 90.40 |
| Cardiovascular Health and Risk Factors | Lifetime | 900 | CN 104 | 90.09 |
| Cerebrovascular and genetic disorders | Lifetime | 715 | CN 26 | 79.56 |
| Acute Ischemic Stroke Management | 2021-2025 | 2 | CN 1 | 99.92 |
| Cerebrovascular and Carotid Artery Diseases | 2021-2025 | 5 | CN 1 | 99.84 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 1 | CN 1 | 98.89 |
| Stroke Rehabilitation and Recovery | 2021-2025 | 6 | CN 1 | 99.78 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 3 | CN 1 | 99.56 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 19 | CN 1 | 99.59 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 9 | CN 1 | 99.66 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 24 | CN 4 | 98.37 |
| Intracerebral and Subarachnoid Hemorrhage Research | 2021-2025 | 32 | CN 6 | 98.48 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 34 | CN 3 | 97.49 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 115 | CN 36 | 97.34 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 65 | CN 2 | 98.27 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 93 | CN 14 | 97.13 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 430 | CN 11 | 96.92 |
| S100 Proteins and Annexins | 2021-2025 | 47 | CN 6 | 91.99 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 128 | CN 23 | 92.20 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 314 | CN 20 | 95.16 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 380 | CN 137 | 91.08 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 749 | CN 64 | 88.60 |
| Traumatic Brain Injury and Neurovascular Disturbances | 2021-2025 | 915 | CN 70 | 89.86 |
| Neurological Complications and Syndromes | 2021-2025 | 94 | CN 14 | 87.73 |
| Folate and B Vitamins Research | 2021-2025 | 298 | CN 82 | 83.31 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 158 | CN 47 | 84.40 |
| Neurological and metabolic disorders | 2021-2025 | 85 | CN 10 | 81.45 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 498 | CN 204 | 80.73 |
| Cerebrovascular and genetic disorders | 2021-2025 | 82 | CN 8 | 82.56 |
| Bone and Joint Diseases | 2021-2025 | 562 | CN 143 | 78.52 |
| Clinical practice guidelines implementation | 2021-2025 | 845 | CN 53 | 67.68 |
| Moyamoya disease diagnosis and treatment | 2021-2025 | 532 | CN 174 | 69.09 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 824 | CN 50 | 53.75 |
| Studies on Chitinases and Chitosanases | 2021-2025 | 376 | CN 178 | 53.44 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 673 | CN 190 | 46.31 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 799 | CN 238 | 35.97 |
